Pre-Lung transplant reflux testing demonstrates high prevalence of gastroesophageal reflux in cystic fibrosis and reduces chronic rejection risk

Table 1 Differences in demographics, transplant risk, reflux parameters, and post-transplant management between cystic fibrosis subjects receiving and not receiving pre-transplant gastroesophageal reflux evaluation, n (%)

Covariate	CF patients with pre-transplant reflux testing (n = 41)	CF patients without pre-transplant reflux testing (n = 19)	P value
Male gender	21 (51.2)	9 (47.4)	1.00
Age at lung transplant	35.8 ± 8.21	30.1 ± 7.89	0.01
Body mass index	20.4 ± 2.51	19.4 ± 1.97	0.11
Caucasian race	41 (100)	19 (100)	1.00
FEV1 before transplant	0.84 ± 0.36)	0.75 ± 0.22	0.24
LVEF before transplant	0.60 ± 0.05	0.59 ± 0.05	0.52
Bilateral lung transplant	41 (100)	19 (100)	1.00
CMV mismatch	15 (36.6)	6 (31.6)	0.78
High-risk donor	0	0	1.00
GER symptoms before transplant	22 (53.7)	5 (26.3)	0.06
Pre-transplant PPI use	27 (65.8)	16 (84.2)	0.22
Abnormal testing/Acid reflux	24 (58.4)	-
Post-transplant PPI use	34 (82.9)	17 (89.5)	0.70
Post-transplant Nissen fundoplication	8 (19.5)	0 (0)	0.05
Any infection	35 (85.4)	17 (89.5)	1.00
Acute rejection	12 (29.3)	7 (36.8)	0.56
Chronic rejection/CLAD	9 (21.9)	12 (63.1)	0.02
Death (All-cause)	8 (19.5)	8 (42.1)	0.11
Death (Pulmonary)	5 (12.2)	6 (31.6)	0.09

CF: Cystic fibrosis; FEV1: Forced expiratory volume in 1 second; LVEF: Left ventricular cardiac ejection volume; CMV: Cytomegalovirus; GER: Gastroesophageal reflux; PPI: Proton pump inhibitor; CLAD: Chronic lung allograft dysfunction.